ARLINGTON, VA / ACCESSWIRE / October 11, 2016 / PhaseRx, Inc. (NASDAQ:PZRX) will be presenting at this year's The MicroCap
Conference on October 24-25 in Philadelphia at the Hotel Monaco, along with 60 other companies in the microcap universe.
The MicroCap Conference is an exclusive event for investors who specialize in small and microcap stocks. It is an opportunity to
be introduced to and speak with management at some of the most attractive small companies, learn from various expert panels, and
mingle with other microcap investors.
This event is free for private and institutional investors - to learn more, please click here.
About PhaseRx, Inc.
PhaseRx is a biopharmaceutical company developing a portfolio of mRNA products to correct life-threatening inherited liver
diseases in children. PhaseRx's initial product development focus is on urea cycle disorders, a group of rare genetic diseases that
generally present before the age of 12 and are characterized by the body's inability to remove ammonia from the blood. The
company's i-ERT approach is enabled by its proprietary Hybrid mRNA TechnologyTM platform and is applicable to a significant number
of inherited liver diseases. PhaseRx is headquartered in Seattle.
SOURCE: PhaseRx, Inc.
